MXCT

Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.

The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies.

Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.